OKY-1581

OKY-1581 (5-100 mg; subcutaneous injection; oral administration) exerts a dose-dependent inhibitory effect on TxB₂ production during collagen-induced platelet aggregation in male New Zealand rabbits (accompanied by increased levels of PGE and PGF). The effect reaches its peak at 2 h after administration, shows no impact on platelet aggregation, and persists for up to 48 h at the 100 mg dose^[1].
OKY-1581 (160 mg; intravenous bolus, administered immediately after subarachnoid hemorrhage; 4 gm/50 mL/24 hours; continuous intravenous infusion until sacrifice at 4 days post-subarachnoid hemorrhage) potently and statistically significantly inhibits late cerebral vasospasm (88.1% reduction) and moderately inhibits early cerebral vasospasm (69.3% reduction) in a canine subarachnoid hemorrhage model, while preventing internal elastic lamina shrinkage without altering subarachnoid hemorrhage-induced endothelial or smooth muscle cell damage^[2].
OKY-1581 (100-500 mg/kg; p.o.; daily; 14-30 days) dose-dependently increases the activities of peroxisomal and mitochondrial lipid metabolic enzymes in the liver of normal male Wistar rats, induces hepatomegaly, and reduces lipid levels in serum and liver, with the maximal effect observed at a daily dose of 500 mg/kg for consecutive 30 days^[4].